
The study of 99 patients found that those with maximal evaluable lesion size (MLS) ≥35 mm had significantly worse progression-free and overall survival. Karnofsky performance status <80%, non-clear cell histology, and large MLS independently predicted outcomes. A new prognostic model using these factors stratifies mRCC patients effectively for nivolumab plus ipilimumab treatment.
Like
Save
Share